Literature DB >> 15976969

Is tissue-plasminogen activator gene polymorphism a risk factor for venous thromboembolism in every population?

I Kivilcim Oguzulgen1, Numan Ekim, Ferda Oner Erkekol, Buket Altinok, Nejat Akar.   

Abstract

BACKGROUND: Tissue-plasminogen activator is a key protein of fibrinolytic system. In recent years the relation between t-PA, its genetic polymorphisms and arterial or venous thrombosis were investigated in different populations. The aim of this study is to investigate the role of t-PA gene polymorphism in Turkish venous thromboembolism (VTE) patients.
METHODS: A case-control study was performed. We investigated the t-PA insertion/deletion (I/D) polymorphism in 93 VTE patients and 146 controls without VTE. Recurrent cases and documented risk factors for PTE were recorded.
RESULTS: Cases and controls did not differ with respect to the different t-PA genotypes. The prevalence of I allele was 44.1%, 44.5% in cases and controls respectively (OR = 0.95, 95% CI: 0.78-1.24, p > 0.05). Different t-PA genotypes had no effect on recurrent disease. No gender difference was observed with respect to the different t-PA genotypes. There was no significant difference for genotype frequency between PTE patients with documented risk factors and unprovoked cases.
CONCLUSIONS: In conclusion there was no association between t-PA genotype and VTE in this group of Turkish population. It was also found that genotype frequencies for t-PA in both VTE and control subjects seems different from those reported from western part of the world. ABBREVIATED ABSTRACT: The aim of this study is to investigate the role of t-PA gene polymorphism in Turkish VTE patients. We investigated 93 VTE patients and 146 controls without VTE. Cases and controls did not differ with respect to the different t-PA genotypes. The prevalence of I allele was 44.1%, 44.5% in cases and controls respectively (OR = 0.95, 95% CI: 0.78-1.24, p > 0.05). Different t-PA genotypes had no effect on recurrent disease. No gender difference was observed with respect to the different t-PA genotypes. There was no significant difference for genotype frequency between PTE patients with documented risk factors and unprovoked cases. In conclusion there was no association between t-PA genotype and VTE in this group of Turkish population. It was also found that genotype frequencies for t-PA in both VTE and control subjects seems different from those reported from western part of the world.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15976969     DOI: 10.1007/s11239-005-0941-5

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN: 0929-5305            Impact factor:   2.300


  15 in total

Review 1.  Role of hemostatic gene polymorphisms in venous and arterial thrombotic disease.

Authors:  D A Lane; P J Grant
Journal:  Blood       Date:  2000-03-01       Impact factor: 22.113

2.  The role of the t-PA I/D and PAI-1 4G/5G polymorphisms in African-American adults with a diagnosis of myocardial infarction or venous thromboembolism.

Authors:  W C Hooper; C Lally; H Austin; M Renshaw; A Dilley; N K Wenger; D J Phillips; C Whitsett; P Rawlins; B L Evatt
Journal:  Thromb Res       Date:  2000-08-01       Impact factor: 3.944

3.  Alu-repeat polymorphism in the gene coding for tissue-type plasminogen activator (t-PA) and risks of myocardial infarction among middle-aged men.

Authors:  P M Ridker; M T Baker; C H Hennekens; M J Stampfer; D E Vaughan
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-09       Impact factor: 8.311

4.  Determinants of tPA antigen and associations with coronary artery disease and acute cerebrovascular disease.

Authors:  A M Carter; A J Catto; P J Grant
Journal:  Thromb Haemost       Date:  1998-10       Impact factor: 5.249

5.  Tissue plasminogen activator and risk of myocardial infarction. The Rotterdam Study.

Authors:  J G van der Bom; P de Knijff; F Haverkate; M L Bots; P Meijer; P T de Jong; A Hofman; C Kluft; D E Grobbee
Journal:  Circulation       Date:  1997-06-17       Impact factor: 29.690

6.  Disordered "fibrinolytic potential" in coronary heart disease.

Authors:  I D Walker; J F Davidson; I Hutton; T D Lawrie
Journal:  Thromb Res       Date:  1977-03       Impact factor: 3.944

7.  Deficient t-PA release and elevated PA inhibitor levels in patients with spontaneous or recurrent deep venous thrombosis.

Authors:  I Juhan-Vague; J Valadier; M C Alessi; M F Aillaud; J Ansaldi; C Philip-Joet; P Holvoet; A Serradimigni; D Collen
Journal:  Thromb Haemost       Date:  1987-02-03       Impact factor: 5.249

8.  Endogenous tissue-type plasminogen activator and risk of myocardial infarction.

Authors:  P M Ridker; D E Vaughan; M J Stampfer; J E Manson; C H Hennekens
Journal:  Lancet       Date:  1993-05-08       Impact factor: 79.321

9.  Allelic dimorphism in the human tissue-type plasminogen activator (TPA) gene as a result of an Alu insertion/deletion event.

Authors:  M Ludwig; K D Wohn; W D Schleuning; K Olek
Journal:  Hum Genet       Date:  1992-02       Impact factor: 4.132

10.  Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group.

Authors:  S G Thompson; J Kienast; S D Pyke; F Haverkate; J C van de Loo
Journal:  N Engl J Med       Date:  1995-03-09       Impact factor: 91.245

View more
  1 in total

1.  Genetic risk factors in recurrent venous thromboembolism: A multilocus, population-based, prospective approach.

Authors:  Robert Y L Zee; Vadim Bubes; Sanjay Shrivastava; Paul M Ridker; Robert J Glynn
Journal:  Clin Chim Acta       Date:  2009-04       Impact factor: 3.786

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.